Swissmedic发布变更通知技术解释I-SMI.TI.22e第4.0版,列出MPLO第41条第2款需报告的重大变更
瑞士Swissmedic:需要申报的 重大变更 清单!
Swissmedic发布技术解释《依据药品许可条例第41条的变更通知》第4.0版(文件号I-SMI.TI.22e),取代2025年5月21日的第3.0版。
近日,瑞士药品监管局(Swissmedic)发布技术解释《依据药品许可条例第41条的变更通知》第4.0版,文件号I-SMI.TI.22e,取代2025年5月21日的第3.0版。文件共6页,说明瑞士各检查机构如何理解《药品许可条例》(MPLO,SR 812.212.1)第41条第2款,并给出"哪些变更算重大变更、必须向Swissmedic报告"的清单。
这份清单里,与制药企业日常最相关的几条是:洁净区结构或技术改造、温控仓储区新建或扩建、注射用水/纯化水/洁净蒸汽系统新建或升级、无菌产品重大工艺设备安装、MES/ERP等复杂计算机化系统上线、用电子记录系统替代纸质批记录、在生产和供应环节引入或更换带人工智能/机器学习功能的软件、引入连续制造或PAT等新技术、由专线改为多产品共线、以及引入更高生物安全级别的生物体或新型转基因生物。带星号的条目对GDP(流通/批发)企业同样适用。
版本4.0的实质变化在提交渠道:变更通知今后只能通过Swissmedic Portal在线提交,此前的eGov服务与纸质通知表不再使用;第1章与第4章只是编辑性调整。文件同时给出时间要求:变更通知一般应在实施之前提交,重大技术改造、厂房扩建或新线上马建议至少提前6个月;Swissmedic收到通知后30天内以书面形式提出异议。
下面是全文对照,英文原文在上,中文译文在下;表格按原文结构转录。
Notifications according to Article 41, MPLO — Technical Interpretation (I-SMI.TI.22e, V4.0)
依据药品许可条例第41条的变更通知——技术解释(I-SMI.TI.22e,第4.0版)
Document valid from: 23.09.2026 | Document number: I-SMI.TI.22e, Version 4.0 | Classification: Public | Replaced document: I-SMI.TI.22e_03 dated 21.05.2025
生效日期:2026年9月23日|文件号:I-SMI.TI.22e,第4.0版|密级:公开|取代文件:I-SMI.TI.22e_03(2025年5月21日)
Author: Paula Walser (16.09.2026) | Technical verification: Federico Cimini (18.09.2026) | Formal verification (Release VS-QMI): Michelle Scheidegger (23.09.2026)
编制:Paula Walser(2026年9月16日)|技术审核:Federico Cimini(2026年9月18日)|正式审核(VS-QMI发布):Michelle Scheidegger(2026年9月23日)
1 Purpose and scope
1.目的与适用范围
Article 41 of the Medicinal Products Licensing Ordinance (MPLO; SR 812.212.1) defines that all major changes to facilities, equipment, systems or procedures used in
《药品许可条例》(MPLO,SR 812.212.1)第41条规定,用于下列活动的设施、设备、系统或程序中,所有重大变更
· manufacturing (including testing),
· 生产(包括检验);
· import or export of medicinal products (incl. active product ingredient and intermediates) or ATMP
· 药品(包括原料药和中间体)或ATMP的进口或出口;
· wholesale trading or trading abroad with medicinal products or ATMP
· 药品或ATMP的批发贸易或境外贸易;
· brokerage or agency activities in connection with such products, or collection of blood
· 与上述产品相关的居间或代理活动,或血液采集;
which may have a quality relevant impact should be notified to Swissmedic by the establishment licence holder providing the respective required information.
只要可能产生质量相关影响,均应由持证企业向Swissmedic报告,并提供各自所需的信息。
This Technical Interpretation outlines the understanding of paragraph 2 of this article by the Swiss inspectorates. It is also intended to provide licence holders with information on which changes Swissmedic considers to be major under article 41, paragraph 2 of the MPLO and therefore to be reportable.
本技术解释阐述了瑞士各检查机构对该条第2款的理解,也旨在告知持证企业:按照MPLO第41条第2款,哪些变更被Swissmedic视为重大变更、因而需要报告。
Note that this document is not aimed at instructing companies on their own internal categorisation of changes, as this is their sole responsibility, together with the GMP/GDP-compliant implementation of the associated required measures.
需要注意的是,本文件并非指导企业如何在其内部对变更进行分类——这属于企业自身的责任,与之相关的必要措施也应由企业按GMP/GDP要求实施。
This Technical Interpretation applies to the Swiss inspectorates, which conduct inspections under the jurisdiction of Swissmedic (i.e., the Swissmedic inspectorate and the inspectorates of the cantons according to art. 60 TPA), subsequently referred to as the inspectorates. It can be used by companies as a basis for assessing the need to notify to Swissmedic of major changes.
本技术解释适用于在Swissmedic管辖下开展检查的瑞士各检查机构(即Swissmedic检查机构,以及根据《治疗产品法》第60条设立的各州检查机构),下文统称"检查机构"。企业可将其作为评估是否需要就重大变更向Swissmedic报告的参考依据。
2 Basics
2.依据
· Therapeutic Products Act (TPA; SR 812.21), Article 69
· 《治疗产品法》(TPA,SR 812.21)第69条
· Medicinal Products Licensing Ordinance (MPLO; SR 812.212.1)
· 《药品许可条例》(MPLO,SR 812.212.1)
· Transplantation Act (TxA; SR 810.21)
· 《移植法》(TxA,SR 810.21)
· Ordinance on Fees Levied by the Swiss Agency for Therapeutic Products (FeeO-Swissmedic; SR 812.214.5)
· 《瑞士治疗产品管理局收费条例》(FeeO-Swissmedic,SR 812.214.5)
3 Definitions and abbreviations
3.定义与缩略语
Abbreviation | Meaning |
|---|---|
ATMP | TpP/GT/GMO |
ERP | Enterprise Resource Planning |
LLM | Large Language Model |
ML | Machine Learning |
MPLO | Medicinal Products Licensing Ordinance (SR 812.212.1) |
PQR | Product Quality Review |
TPA | Therapeutic Products Act |
TpP/GT/GMO | Transplant products/gene therapy products/genetically modified organisms |
ATMP(先进治疗药品)在瑞士法规体系中按TpP/GT/GMO(移植产品/基因治疗产品/转基因生物)分类管理,故原文将其释义直接写为TpP/GT/GMO。
4 Notifiable changes per article 41, paragraph 2 of the MPLO
4.按MPLO第41条第2款需报告的变更
It is the responsibility of any licence holder to assess whether a change falls within the scope of article 41, paragraph 1 of the MPLO and accordingly requires an application for the adaptation of the establishment licence, or whether it needs to be notified according to article 41, paragraph 2.
判断一项变更属于MPLO第41条第1款范围、因而需要提出许可证变更申请,还是属于第41条第2款、只需报告,是每个持证企业自己的责任。
A list of common examples of major changes within the context of article 41, paragraph 2 of the MPLO, requiring notification to Swissmedic, as described in chapter 5 of this Technical Interpretation, can be found in table 1. This list, which does not claim to be exhaustive, primarily applies to licence holders with manufacturing activities. However, those change types marked with an asterisk (*) may also pertain to companies operating in the GDP field (e.g., companies involved in distribution or wholesale activities, etc.).
MPLO第41条第2款语境下常见的重大变更实例(需向Swissmedic报告、按本技术解释第5章程序办理)见表1。该清单并不声称穷尽所有情形,且主要适用于有生产活动的持证企业;但带星号(*)的变更类型也可能适用于从事GDP领域业务的公司(例如从事流通或批发活动的企业等)。
The notification of a major change under article 41, paragraph 2 of the MPLO must generally precede the implementation of the system, equipment, facility or procedure to which the change applies. Companies should submit the change notification with a reasonable margin of time before implementation, as the evaluation to be carried out by Swissmedic to assess and approve the change may, depending on its nature and intended use, require time-consuming, in-depth evaluations and possibly an inspection. For example, in the case of a major technical modification, an extension of the plant or the start-up of a new manufacturing line, it is recommended that the corresponding change notification be submitted at least 6 months before the planned completion of the respective qualification activities or the first use for GMP purposes.
按MPLO第41条第2款,重大变更的通知一般应在相关系统、设备、设施或程序实施之前提交。企业应在实施前留出合理的时间余量,因为Swissmedic为评估和批准该变更所开展的评价,可能依变更性质与预期用途需要耗时深入的评估,甚至可能需要现场检查。例如,对于重大技术改造、厂房扩建或新生产线启用,建议在相应确认活动计划完成之日、或首次用于GMP目的之日至少6个月前提交变更通知。
The timing of Swissmedic’s formal decision may depend significantly on the nature of the notified change. In certain cases, it may be necessary for a company to begin implementing the change, and to use the affected plant, system, equipment, or process, before receiving Swissmedic’s decision that it has no objections. This may be required, for example, to generate the necessary supporting data and documentation.
Swissmedic作出正式决定的时间,可能在很大程度上取决于所报告变更的性质。在某些情况下,企业可能需要在收到Swissmedic"无异议"的决定之前就开始实施变更、使用受影响的厂房、系统、设备或工艺——例如为了生成必要的支持性数据与文件。
It is therefore essential to emphasize that, in any case, the company must ensure, through robust, well-documented measures and effective change management, that the plant, system, equipment, or process affected by the notified change is only released for use once all applicable requirements have been fulfilled. If batches are produced during the course of the change realisation, these measures must also guarantee that such batches are not released for use in animals or humans until Swissmedic has confirmed that it has no objections to the change implementation.
因此必须强调:无论如何,企业都应以稳健、记录完备的措施和有效的变更管理,确保受该变更影响的厂房、系统、设备或工艺只有在全部适用要求均已满足后才放行使用。如果在变更实施过程中生产了批次,这些措施还必须保证:在Swissmedic确认对变更实施无异议之前,相关批次不得放行用于动物或人。
Table 1: Major changes (art. 41, para. 2 MPLO) to be notified to Swissmedic
表1:需向Swissmedic报告的重大变更(MPLO第41条第2款)
Area | Change |
|---|---|
Building / | Construction or revamping involving structural or technical measures of clean rooms used in manufacturing |
Construction of new buildings or lines used for secondary packaging of products (drug products). | |
New production buildings or lines for the manufacture of chemically synthesized active ingredients. | |
Construction or extension of temperature-controlled storage area* (e.g., climate chamber/rooms for controlled room temp./cold or cool storage, high rack storage area) for medicinal products, ATMPs, active substances or intermediates. Not included are stand-alone equipment like refrigerators, storage area for raw materials (incl. excipients), cell banks, packaging materials, stability and QC samples. | |
Construction of rooms for collecting and processing of blood donations. | |
Construction of new QC buildings or laboratory areas for the testing of medicinal products, active ingredients, intermediates, ATMP, in-process control samples or stability study samples, or relocation of the above-mentioned analytical activities into rooms of another building or area (incl. other floors of same building). | |
Changes in the zone concept and/or classification of established clean room areas, incl. transfer of defined manufacturing activities into area with lower clean room requirements and adaptation of the pressure cascade strategy (e.g., reversal of pressure differences or provision of pressure sinks). | |
Clean | New system or upgrade of existing system for the generation, storage or distribution of water for injection (WFI), purified water (PW) and clean steam used in manufacturing. |
Introduction of new systems for the generation or distribution of process gases used in the manufacture of sterile medical products, sterile active ingredients or of low bioburden drug substances, or ATMPs. | |
Equipment | Installation of new major processing equipment for sterile products manufacturing (e.g., filling line, RABS, isolator, freeze dryer, or depyrogenation tunnel), incl. equipment used for the terminal sterilization of products (e.g., autoclave). |
Introduction of new complex major computerized systems* used for the purpose of process control in manufacturing (incl. automation systems, manufacturing execution system) or material management systems (e.g., ERP system). Not included are software updates of the above-mentioned reportable computerized systems. Reportable is also the replacement or supplementation of paper-based manufacturing batch records or laboratory testing records by electronic record systems. Not reportable is the introduction of computerized systems used to manage personnel data (incl. learning management systems), SOPs or GMP records such as deviations, changes, complaints, audits or qualification documentation. | |
Introduction or replacement of computerized system software with Artificial Intelligence/Machine Learning software* for use in manufacturing or supply (e.g., LLM for managing complaints, adverse drug reaction notification, PQRs, batch record review; ML applied to downstream processing to increase yield, or for automated visual inspection, etc.). | |
Introduction of solvent recycling plants. | |
Introduction of a new technology in production incl. new technology used for control strategies (e.g., continuous manufacturing, new type of major manufacturing equipment, new approach for container closure integrity testing or visual control of parenterals, 3D printing processes). | |
Introduction of a new technology in quality control (e.g., introduction of rapid microbiological methods or methods using chemometric statistics), of new applications using artificial intelligence systems or introduction of process analytical technology (PAT) for process control, real-time release testing or parametric release strategy. The introduction of new analytical devices available on the market as standard and whose application is described in pharmacopoeias or comparable regulations (e.g., new HPLCs, Fourier-transform infrared spectrometer, GC-MS, etc.) does not require notification. | |
Product(s) | Change from a dedicated to multi-product manufacturing line/facility. |
Introduction of an organism of higher biosafety level or new type of genetically modified organism (incl. pathogenic or alien organisms that have been genetically modified) into an established manufacturing facility/building. |
* 带星号的变更,对有生产活动的企业以及从事GDP领域业务的企业都可能相关。
5 Notification procedure
5.通知程序
The change notifications, together with the corresponding relevant documentation, must be submitted exclusively in electronic form using the Swissmedic Portal. This guarantees secure data exchange between companies and Swissmedic.
变更通知连同相应的相关文件,必须通过Swissmedic Portal以电子形式提交——且仅限于此渠道。这保证了企业与Swissmedic之间的数据安全交换。
To be able to use the Swissmedic Portal, the designated company employees must first request access to the system. Further details on registration and use of the Swissmedic Portal is available in the following information sheet “Instructions on User Management for Swissmedic Portal Roles in the eIAM Portal“.
要使用Swissmedic Portal,企业指定的员工须先申请系统访问权限。有关注册与使用Swissmedic Portal的更多细节,见信息说明《eIAM门户中Swissmedic Portal角色用户管理指引》。
Instructions on how to enter and submit change notifications in the system using the data entry interface, as well as information on the available functions for communication with Swissmedic regarding submitted notifications, can also be found in the information sheet “Swissmedic Portal - Standard Functions Licences - Major Changes” on the Swissmedic website.
关于如何通过数据录入界面在系统中填写并提交变更通知,以及与已提交通知相关的、与Swissmedic沟通的可用功能,见Swissmedic网站上的信息说明《Swissmedic Portal—许可证标准功能—重大变更》。
When submitting a notification, the applicant shall ensure that any relevant supporting documentation is uploaded to the system as PDF files.
提交通知时,申请人应确保所有相关支持性文件均以PDF格式上传至系统。
If the major change concerns various establishment licences (e.g., establishment licence for medicinal products and for TpP/GT/GMO), a change notification form must be submitted for each establishment licence.
如果重大变更涉及多项企业许可证(例如药品许可证与TpP/GT/GMO许可证),则须针对每项许可证分别提交变更通知表。
The information to be provided includes, in addition to a description of the change, details of the planned realisation timelines, a list of the operational sites impacted, an overview of the planned measures and, if applicable, of individual main phases of the change implementation briefly summarized and, where appropriate, supplemented with supporting documents (e.g., change control, layout, project plan and/or qualification documentation).
需提供的信息除变更描述外,还包括:计划实施时间表的细节、受影响运营场点的清单、拟采取措施的概述,以及在适用情况下对变更实施各主要阶段的简要汇总,并视需要附支持性文件(例如变更控制、平面布局、项目计划和/或确认文件)。
The documentation will be assessed and the company will be informed whether additional information or time is required or if an inspection needs to take place before approval of the change. Any objections will be communicated in written form within 30 days after receipt of the notification. Fees are charged at cost.
文件将被评估,企业会被告知是否需要补充信息或更多时间,或在批准变更前是否需要开展检查。任何异议将在收到通知后30天内以书面形式告知。费用按成本收取。
Changes that have an impact on the establishment licence (art. 41, para. 1 MPLO) should be submitted only as a change request of the establishment licence.
对企业许可证产生影响的变更(MPLO第41条第1款),应仅作为许可证变更申请提交。
Changes affecting the market authorisation of commercial products or investigational medicinal applications should additionally be submitted in accordance with the respective applicable procedure.
影响上市产品上市许可或临床试验用药申请的变更,还应按各自适用的程序另行提交。
6 Changes to the previous version
6.与上一版的差异
· Chapter 1 and 4: minor editorial adaptations
· 第1章与第4章:编辑性小幅调整。
· Chapter 5: Consideration of the introduction of the new Swissmedic Portal for the submission of change notifications. This portal replaces the former eGov Service system, eliminates the need for a paper-based notification form, and enables user-friendly communication between the notifying company and Swissmedic.
· 第5章:纳入新的Swissmedic Portal作为变更通知提交渠道。该门户取代此前的eGov服务系统,取消了纸质通知表,并使申报企业与Swissmedic之间的沟通更便捷。
Notes on Terms and Background
译注:术语与背景
Swissmedic / MPLO
Swissmedic即瑞士药品监管局(Swiss Agency for Therapeutic Products),瑞士的药品与医疗器械监管机构。MPLO为《药品许可条例》(Medicinal Products Licensing Ordinance,SR 812.212.1),SR编号为瑞士联邦法规汇编的分类号。
Art. 41 para. 1 vs para. 2
第41条第1款针对"许可证内容本身的变更",须提出许可证变更申请(change request);第2款针对"可能影响质量的重大变更",须向Swissmedic报告(notification)。两者走不同通道,本文件只解释第2款。
Establishment licence
企业许可证/场所许可证,指按瑞士法律对生产、进口、批发等活动的场所颁发的许可;本文件语境下既可能是药品许可证,也可能是TpP/GT/GMO许可证。
ATMP / TpP/GT/GMO
ATMP(先进治疗药品)在瑞士按TpP/GT/GMO(移植产品/基因治疗产品/转基因生物)分类管理,因此文件中的定义表把ATMP直接释义为TpP/GT/GMO。
* GDP relevant
带星号的变更类型对GDP(药品流通质量管理规范)领域企业也可能适用,例如温控仓储区新建或扩建、复杂计算机化系统(含ERP)、AI/ML软件等。
Document naming
I-SMI.TI.22e为Swissmedic内部文件编号:I(Inspectorate,检查部门)—SMI(Swissmedic)—TI(Technical Interpretation,技术解释)—22e(第22号文件,e为英文版)。
Original document
原文链接:https://www.swissmedic.ch/dam/swissmedic/de/dokumente/bewilligungen/inspektorat/i-smi_tj_22e_notifications_art_41_mplo.pdf.download.pdf/I-SMI.TI.22e_Notifications_Art_41_MPLO.pdf
来源:制药经理人 · mp.weixin.qq.com